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DLB consensus pathologic guidelinesucleinopathies, Parkinson disease (PD) or brainstem predominant type of Lewy
body disease, and dementia with Lewy bodies (DLB), are neurodegenerative multisystem disorders with
widespread occurrence of α-synuclein containing deposits in the central, peripheral, and autonomic systems.
For both Lewy body-related disorders staging/classiﬁcation systems based on semiquantitative assessment
of the distribution and progression pattern of α-synuclein pathology are used that are considered to be
linked to clinical dysfunctions. In PD a six-stage system is suggested to indicate a predictable sequence of
lesions with ascending progression from medullary and olfactory nuclei to the cortex, the ﬁrst two
presymptomatic stages related to incidental Lewy body disease, stages 3 and 4 presenting with motor
symptoms and the last two (cortical) stages frequently associated with cognitive impairment. DLB, according
to consensus pathologic guidelines, by semiquantitative scoring of α-synuclein pathology (Lewy body
density and distribution) in speciﬁc brain regions, is distinguished into three phenotypes (brainstem,
transitory/limbic and diffuse cortical), also considering concomitant Alzheimer-related pathology. Recent
retrospective clinico-pathologic studies, although largely conﬁrming the staging system, particularly for
younger onset PD with long duration, have shown that between 6.3 and 43% of cases did not follow the
proposed caudo-rostral progression pattern of α-synuclein pathology. In 7 to 8.3% of clinically manifested PD
cases with synuclein inclusions in midbrain and cortex corresponding to LB stages 4–5 the medullary nuclei
were spared, whereas mild parkinsonian symptoms were already observed in stages 2 and 3. There is
considerable clinical and pathologic overlap between PD (with or without dementia) and DLB, corresponding
to Braak LB stages 5 and 6, both frequently associated with variable Alzheimer-type pathology. Dementia
often does not correlate with progressed stages of Lewy body pathology, but is related to concomitant
Alzheimer lesions or mixed pathologies. There is no relationship between Braak LB stages and clinical
severity of PD. Therefore, the predictive validity of this concept is doubtful, since in large unselected autopsy
series 30 to 55% of elderly subjects with widespread α-synuclein pathology (Braak stages 5–6) revealed no
deﬁnite neuropsychiatric symptoms or were not classiﬁable, indicating compensatory mechanisms of the
brain. The causes and molecular basis of rather frequent deviations from the proposed caudo-rostral
progression of α-synuclein pathology in PD, its relation to the onset of classical parkinsonian symptoms, the
causes for the lack of deﬁnite clinical symptoms despite widespread α-synuclein pathology in the nervous
system, their relations to Alzheimer-type lesions, and the pathophysiologic impact of both pathologies
remain to be further elucidated.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Among proteinopathies, a heterogenous group of neurodegenera-
tive disorders, characterized by intra- and extracellular accumulation
of abnormal ﬁlament proteins, Lewy body (LB)-associated disorders,
such as Parkinson disease (PD) and dementia with Lewy bodies (DLB)
show protein inclusions in neurons and neurites (LBs and Lewy
neurites/LNs), glia, and presynaptic terminals [1], with α-synucleinll rights reserved.(αSyn) as their major component (for rev see [2]). Given the
fundamental nature of the αSyn containing lesions, these and other
disorders, such as autonomic failure, LB dysphagia, and multiple
system atrophy (MSA) have been summarized asα-synucleinopathies
[3,4]. PD or brainstem type of LB disease [5,6] is the most common
neurodegenerative movement disorder in the elderly, with progres-
sive degeneration of the dopaminergic nigrostriatal system and other
neuronal networks caused by loss of pigmented neurons in the
substantia nigra compacta (SNc) and many other subcortical nuclei
associatedwithwidespread occurrence of LBs and LNs in the brain and
speciﬁc nuclei of the spinal cord. PD-related lesions are not conﬁned to
the central nervous system, but also involve autonomic nuclei,
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adrenal medulla, salivary gland and skin [7–23], clearly indicating that
PD is a multisystem disorder (for rev. see [2,8,24]. This is in agreement
with animal studies demonstrating that lesions to the SN or DA
pathways alone do not accurately model human PD [25]. DLB, the
secondmost frequent cause of dementia in the elderly after Alzheimer
disease (AD), with the core neuropsychiatric features of ﬂuctuating
consciousness, visual hallucinations and parkinsonism, is morpholo-
gically featured by a variable burden of a synucleinopathy with (often
widespread) cortical LBs and various degrees of AD-related pathology
[5,6].
The distribution pattern of αSyn pathology within selectively
vulnerable neuronal populations is considered to be intimately linked
to the clinical dysfunctions seen in both disorders, αSyn lesions in the
brainstem been mainly claimed to be responsible for extrapyramidal
motor symptoms, whereas cognitive impairment has been attributed
to the limbic and neocortical spread of LB lesions [26–30]. Thus, PD
and DLB are believed to represent phenotypes in a continuum within
the spectrum of LB disorders, wherein the clinical manifestations
predominantly depend on the anatomical distribution and load of
αSyn pathology [6,13,31–33]. Despite clinical, biochemical and
morphological similarities and dissimilarities, the relations between
the two disorders have been discussed controversially [2,34–39].
Two morphological staging/classiﬁcation systems are currently
used for the assessment of the progressive regional distribution ofFig. 1. Progress and distribution pattern of PD-related neuronal pathology. ab accessory basal
of amygdala, am anteromedial nucleus of thalamus, an abducens motor nucleus, ba basal
second Ammon's horn sector, ca caudate nucleus, cc corpus callosum, ce central nuclei of am
central nucleus of raphe, db nucleus of the diagonal band, dm dorsomedial hypothalamic n
dorsal nuclear complex of vagal nerve, en entorhinal region, fn facial motor nucleus, fo forn
motor nucleus, in infundibular nucleus, ir intermediate reticular zone, lc locus coeruleus,
thalami, lt lateral nuclei of the thalamus,mdmediodorsal nuclei of thalamus,memedial nucl
lemniscus, mm medial mamillary nucleus, ms medial septal nucleus, mt mamillothalamic tr
tract, pe external pallidum, pf parafascicular nucleus, ph posterior hypothalamic nucleu
paraventricular nucleus, re reticular nucleus of the thalamus, rm nucleus raphes magnus,
supraoptic nucleus, sn substantia nigra, sp subpeduncular nucleus, st nucleus of the stria ter
tuberomamillary nucleus, tp tegmental pedunculopontine nucleus, vl ventro-lateral nu
dopaminergic nuclei of ventral tegmentum (paranigral nucleus and pigmented parabrachiaαSyn pathology in PD and DLB [5,6,31,40], the applicability and
clinical relevance of which has been critically discussed recently [41–
43]. Both staging systems, the Braak hypothesis of LB staging in PD
[31] and the DLB consensus guidelines [5,6] were developed in non-
population-based cohorts. The essentials and validity of these two
systems will be critically evaluated based on recent literature and
personal studies.
2. Staging of αSyn inclusion body pathology in sporadic PD
Based on semiquantitative assessment of αSyn-positive inclusions
in 413 postmortem cases including 41 PD cases, 69 with αSyn
inclusions and 58 aged-matched controls, a hypothetic staging system
of brain pathology indicating a predictable sequence with increasing
severity throughout the brain and ascending progression has been
proposed [9,31,44–46]. αSyn pathology was divided into six succes-
sive stages (Fig.1): The earliest lesions were seen in the lowermedulla
oblongata with a few LNs in the dorsal motor nucleus of the vagus
nerve (DMV), in anterior olfactory structures, chieﬂy affecting the
anterior olfactory nucleus embedded in the olfactory tract, some
αSyn-positive aggregates in preganglionic vagal axons [10], and the
enteric neurons system [24], with the nucleus basalis of Meynert
(NBM) and midbrain regions being preserved (Stage 1). More severe
lesions in the DMV with extension to the caudal raphe nuclei and
gigantocellular portions of the adjoining reticular formation, andnucleus of amygdala, ac accessory cortical nucleus of amygdala, ad anterodorsal nucleus
nucleus of amygdala, bn basal nucleus of Meynert, ca1 ﬁrst Ammon's horn sector, ca2
ygdala, cg central grey of mesencephalon, cl claustrum, co cortical nuclei of amygdala, cr
ucleus, dr dorsal nucleus of raphe, ds decussation of superior cerebellar peduncles, dv
ix, gi gigantocellular reticular nucleus, gr granular nucleus of amygdala, hn hypoglossal
ld laterodorsal nucleus of the thalamus, lg lateral geniculate body, li nucleus limitans
ei of amygdala,mfmedial longitudinal fasciculus,mgmedial geniculate body,mlmedial
act, mv dorsal motor nucleus of vagal nerve, oi oliva inferior, os oliva superior, ot optic
s, pi internal pallidum, po pontine grey, pr praepositus nucleus, pu putamen, pv
ru nucleus ruber, sb subiculum, sc superior cerebellar peduncle, sf solitary fascicle, so
minalis, sn subthalamic nucleus, te transentorhinal region, tl lateral tuberal nucleus, tm
clei of thalamus, vm ventromedial hypothalamic nucleus, vn vestibular nuclei, vt
l nucleus), zi zona incerta.
Table 1a
Assignment of Lewy body type based upon pattern of Lewy-related pathology in brainstem, limbic, and neocortical regions [McKeith et al., 2005]
Lewy body type pathology Brainstem regions Basal forebrain/limbic regions Neocortical regions
IX–X LC SN nbM Amygdala Transentorhinal Cingulate Temporal Frontal Parietal
Brainstem-predominant 1–3 1–3 1–3 0–2 0–2 0–1 0–1 0 0 0
Limbic (transitional) 1–3 1–3 1–3 2–3 2–3 1–3 1–3 0–2 0–1 0
Diffuse neocortical 1–3 1–3 1–3 2–3 3–4 2–4 2–4 2–3 1–3 0–2
IX–X = 9th–10th cranial nerve nucleus; LC = locus ceruleus; SN = substantia nigra; nbM = nucleus basalis of Meynert.
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These initial stages (observed in 7% of the cohort) were considered a
(pre)symptomatic and may explain early non-motor (autonomic and
olfactory) symptoms that precede the somato-motor dysfunctions
[47–50]. In stage 3, the LC, the central nucleus of the amygdala, the
tegmental pedunculopontine nucleus and cholinergic nuclei of the
basal forebrain including the NMB are the focus of cytoskeletal
changes and neuronal depletions, the posterolateral and poster-
omedial parts of SNc showing pale bodies (precursors of LBs) [51] and
LBs without neuronal loss with additional involvement of hypotha-
lamic nuclei, while the allocortex and neocortex are preserved. In
stage 4, SNc is severely damaged, and the anteromedial temporal
limbic (transentorhinal) and mesocortex, and amygdala are addition-
ally affected. Stages 3 and 4 have been correlated with clinical motor
symptoms (11% of their cohort). In stage 5, the lesions in the temporal
mesocortex are more striking and from there progress to adjoining
association ﬁelds of the temporal and prefrontal neocortex, while in
stage 6, the lesions involve the neocortex, ﬁrst affecting the high-order
sensory association cortex and prefrontal areas, later progressing to
the primary sensory andmotor areas or involving thewhole neocortex
(Fig.1). The cases with severe pathology (stage 5–6) accounting for 6%
of their cohort, frequently show cognitive decline that relates to the
severity of the neuropathologic stage [10,40]. In another retrospective
study of 25 individuals (17with PD, 8with incidentalαSyn inclusions)
LB pathology and glial cytoplasmic inclusions in striatum were seen
for the ﬁrst time in stage 3 in the medium-sized GABA-ergic spiny
projection neurons that reach both the pallidum and SN reticulata
(SNr), and at stages 5–6 in the large cholinergic interneurons [52].
More recently, the origininal LB staging scheme has been revised,
proposing that AS pathology in PD begins in the olfactory bulb and
within enteric cell plexuses [53]. This has lead to the so-called “dual-
hit hypothesis”, whereby an unknown neurotoxic pathogen enters the
brain either by the nasal route with anterograde progression to the
amygdala and temporal lobe or after gastric entry by subsequent
retrograde and transneuronal transport. Recent studies, however,
have clearly shown that in incidental LB disease (ILBD/preclinial PD)
AS pathology simultaneously occurs in multiple regions of the centralTable 1b
Revised consensus pathological guidelines for scoring cortical LB deposition
Cortical region Brodmann area Anatomy Score
Entorhinal cortex 29 Medial ﬂank of collateral sulcus 0 1 2
Cingulate gyrus 24 Whole gyral cortex 0 1 2
Mid-frontal cortex 8/9 Lateral ﬂank of superior
frontal sulcus
0 1 2
Mid-temporal cortex 21 Inferior surface of superior
temporal sulcus
0 1 2
Inferior parietal lobule 40 Lateral ﬂank of parietal sulcus 0 1 2
Cortical Lewy body score: 0–2 Brainstem-predominant, 3–6 Limbic or ‘transitional’, 7–
10 Neocortical.
For each region, Lewy bodies are counted from the depth of the sulcus to the lip. Counts
are not made over the crest of the gyri except for the cingulate gyrus. Lewy bodies are
predominantly located in deeper cortical layers (layers 5 and 6). In each region a count
of up to 5 Lewy bodies in the cortical ribbon gives a score of 1 in the table. Counts
greater than 5 score as 2. The sum of the ﬁve areas is used to derive the category of
cortical spread (maximum score 10).and peripheral nervous system, which argues against a uniform
caudo-rostral progression of AS pathology [54].
3. Consensus pathologic guidelines for the diagnosis of DLB
According to the initial consensus pathologic guidelines, LBs are
scored semiquantitatively according to the severity and anatomical
distribution, separating brainstem predominant (PD), limbic/transi-
tional and diffuse neocortical types, depending on the anatomical
distribution of theαSyn-positive structures [5]. The revised consensus
guidelines [6] proposed semiquantitative assessment of LB density,
based on αSyn immunohistochemistry in brainstem, basal forebrain,
and in ﬁve cortical regions (Tables 1a, b). However, the stage of AD
pathology is usually not associated with the particular pattern ofαSyn
lesions [55]. A third pattern concentrated on αSyn pathology in
cortical areas [56]. Considering the signiﬁcance and clinical impact of
concomitant AD-related pathology frequently seen in aged subjects
with and without dementia, the revised consensus criteria for DLB
have recommended to take it into account seriously [6] (Table 2). This
protocol was simpliﬁed by excluding the frontal region because of the
common occurrence of occasional LBs in this regions in PD in the
absence of dementia [57].
These guidelines did not provide deﬁnite diagnostic criteria as
these are sometimes mistakenly assumed, and were not included in
the CERAD protocol, which is used for the semiquantitative evaluation
of neuritic plaques and neuroﬁbrillary tangles [58]. On validating the
DLB Consortium's third report on DLB neuropathologic criteria [6],
Fujishiro et al. [59] found this scheme useful for estimating the
likelihood of association between premortem syndrome and post-
mortem ﬁndings, but suggested a possible modiﬁcation of the scheme
is to consider cases with neuritic Braak stage 6 to be low-likelihood
DLB (Table 3). Application of these guidelines in a long autopsy series
of demented elderly patients showed that 49% of LB-positive cases
were not classiﬁable, and modiﬁcation of the McKeith criteria was
proposed [60] (Table 4).
4. Studies to evaluate the reliability of αSyn-related stagings
The proposed staging procedure for αSyn pathology in PD rested,
in part, on the assumption that incidental LB pathology is the ﬁrst
step along a disease continuum [46], but that sporadic PD, like most
neurodegenerative disorders, is not a static but a dynamic biologicTable 2
Assessment of the likelihood that the pathologic ﬁndings are associated with a DLB
clinical syndrome [McKeith et al., 2005]
Alzheimer-type pathology
NIA-Reagan low
(Braak stage 0–II)
NIA-Reagan
intermediate
(Braak stage III–IV)
NIA-Reagan high
(Braak stage V–VI)
Lewy body type pathology
Brainstem-predominant Low Low Low
Limbic (transitional) High Intermediate Low
Diffuse neocortical High High Intermediate
DLB = dementia with Lewy bodies; NIA = National Institute on Aging.
Table 3
Changes in the CDLB criteria with results from prospective cases (modiﬁed from Fujishiro et al., JNEN 2008; 67)
Lewy
bodypathology
Alzheimer pathology
NIA low (Braak stage 0–II) NIA intermediate (Braak stage III–IV) NIA high (Braak stage V) NIA high (Braak stage VI)
No Lewy bodies CDLB low 0/3 CDLB low 0/9 CDLB low 0/3 CDLB low 1/7
Amygdala only CDLB low 0 CDLB low 0 CDLB low 0 CDLB low 0/2
Brainstem CDLB low 0 CDLB low 0 CDLB low 0 CDLB low 0
Limbic CDLB high 2/2 CDLB intermediate 2/2 CDLB low 0/1 CDLB low 2/4
Diffuse CDLB high 6/6 CDLB high 20/21 CDLB intermediate 9/10 CDLB low 1/5
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without PD-related signs and symptoms) represent presymptomatic
(subclinical) correlates of a pathologic condition ultimately leading to
a manifest clinical disease [10,61–63].
Incidental LB disease (iLBD) is the term when LBs are found in the
nervous system in subjects without clinically documented parkinson-
ism or cognitive impairment [62,64]. Epidemiological studies indi-
cated that autonomic symptoms, REM sleep behavioral disorder and
olfactory dysfunction may precede overt extrapyramidal motor
symptoms by years [65–67], resulting from LBs and LNs in the enteric
plexus [10,68], affection of lower brainstem nuclei [69,70] and the
sympathetic cardiac nervous system [71]. Recent studies of iLBD cases
have shown a distribution of LBs similar to that in PD, involving one or
multiple brain areas, some also with sparse LBs in limbic or temporal
cortex (average Braak stage 2.7±0.3) in comparison to deﬁnite PD
cases with more numerous LBs in all regions and signiﬁcantly higher
Braak PD stage (average 4.4±0.3). When both groups were taken
together, a signiﬁcant inverse correlation existed between neuronal
densities in the three anatomical regions studied and the Braak PD
stage [54]. Furthermore, there was decreased TH immunoreactivity in
both the striatum and sympathetic epicardial nerve ﬁbers in cases
with incidental LB pathology compared to normal controls but not
in the same extent as in PD [54,72]. Both striatal TH and VMAT2
(vesicular monoamine transporter 2) immunoreactivity were highly
correlated with SN neuronal loss and Braak PD stage that was also
correlated with SN neuronal loss [73]. On the other hand, incidental
αSyn pathology may affect solely the LC and SN without affection of
the medullary nuclei [74–77]. Incidental LBs are not considered as a
normal aging phenomenon, whereas neuroﬁbrillary tangles increase
with age in the SN [78], and are associated with increasing neuritic AD
stages [79]. These ﬁndings suggest that iLBD is likely a precursor to or
preclinical form of PD, and the lack of symptoms is due to sub-
threshold αSyn pathology. The frequency, distribution, and severity of
LBs in most neurodegenerative diseases (PSP, Pick disease, FTLD, and
CBD) ranging from 8 to 12% was similar to that of normal aged con-
trols, suggesting that in most cases this represents iLBD [80].Table 4
Proposed modiﬁed criteria for categorization of Lewy-related pathology (LRP) in
patients with dementia
Predominant
region
LRP severity scoring with proposed criteriaa Results
SN or medullab Amygdala Cingulate
gyrus
Frontal
cortex
LADRS
n (%)
ADPR
n (%)
Brainstem 1+ in either 0–2 0–1 0 5 (4) 20 (16)
Amygdala 0–1 in both 1+ 0–1 0 23 (18) 24 (19)
Limbic 1+ in either 2+ 1–3 0–1 26 (21) 22 (18)
Neocortical 1+ in either 2+ 2+ 2+ 67 (54) 55 (44)
Mixed Cases not classiﬁable by modiﬁed criteria 4 (3) 5 (4)
Results from two autopsy series ([60], Brain Pathol).
SN = substantia nigra; LADRS = Lewy Body-Associated Dementia Research Study;
ADPR = Alzheimer's Disease Patient Registry; AD = Alzheimer's disease.
a Severity of LRP was scored according to published consensus criteria as none (0),
mild (1), moderate (2), severe (3) or very severe (4).
b For medulla, the highest score in dorsal motor nucleus of the vagus nerve, raphe
nuclei or lateral tegmentum was considered representative and 0 means no LRP in all
three subregions of medulla.Some recent studies have largely conﬁrmed this staging of LB-
related pathology in sporadic PD, showing that all brains of subjects
with clinical PD revealedαSyn-positive inclusions and neuronal losses
inmedullary and pontine nuclei and SN, and additional lesions in NBM
(90–98%), limbic cortex (50–60%), cingulate area (32–46%), frontal
cortex (29–31%), and amygdala (25%), corresponding to LB stages 4 to
6 [3,74]. In a previous study, LBs in SN were found in 99.2% of clinico-
pathologically conﬁrmed PD cases [81]. LB pathology ﬁrst appears in
the ventrolateral part of SNc, spreads to the paranigral nucleus and
then to themedial part, and ﬁnally to the dorsal part of SNc [82]. There
is severe depletion of melanized neurons (45–66%) and of dopami-
nergic neurons immunoreactive for tyrosine hydroxylase (TH) (60–
85%) in the A9 group of SNc, particularly in the ventrolateral tier (91%)
projecting to striosomal compartments of the striatum [83], followed
by the ventromedial (71%) and dorsal parts (56%) [84]. The calbindin
(CAB)-rich compartments show greater cell loss in the caudal and
mediolateral region (98%) than the adjacent matrix. From there, it
spreads to other nigrosomes and ﬁnally to the matrix along a caudo-
rostral, lateromedial and ventrodorsal progression [85]. These changes
differ from age-related lesions in the dorsal tier of SNc that is involved
only in late stages of PD [84,86]. The A10 group of dopaminergic
neurons – ventral tegmental area, nucleus parabrachialis, and para-
brachialis pigmentosus – projecting to the striatal matrix, thalamus
[87], cortical and limbic areas (mesocortico-limbic system) [88] in PD
show less severe involvement (40–50% cell loss), the retrorubral A8
region containing only few dopaminergic but CAB-rich neurons, and
the central periventricular gray suffer little or no degeneration [89].
Others reported greater cell loss in LC (area A6) than in SN in both PD
and AD [90]. Morphometric studies showed a 35–41% reduction of
pigmented SN cells, with severe loss of dopamine transporter (DAT)-
immunoreactive neurons in older persons [91] and increase in the
volume of these cells [92]. Some studies have estimated the neuronal
loss as 4.3% per decade [92], while others have reported almost 10%
[93]. Recent morphometric stereologic studies of the human SN
revealed a signiﬁcant loss of pigmented (−28.3%) and TH-positive
(−36.2%) neurons in older controls compared to younger subjects,
with hypertrophy of cells in older controls, interpreted as a
compensatory mechanism to allow normal motor function despite
cell loss. PD showed a massive loss of SN neurons with signiﬁcant
atrophy of remaining cells (20% of controls), but most of the examined
cases were in the end stage of the disease [94].
A prerequisite of the proposed staging system of αSyn inclusion
pathology is that the extent and severity of lesions increase as the
disease progresses [45]. A study of 21 PD brains by six observers from
ﬁve different institutions examining 11 different brain areas revealed
highly signiﬁcant inter- and intra-rater reliability and supported the
suitability of the staging procedure of αSyn pathology for application
in routine neuropathology and brain banking [95]. However, the
reliability of this staging system has recently been challenged
[3,55,74–76,96,97]. In Braak's cohort of 301 cases (including 176
clinical PD and 106 with incidental LB pathology), only 6.3% of PD
brains diverged from the hypothetical staging scheme of αSyn
pathology, with predominant involvement of olfactory structures
and amygdala, and advanced concomitant AD-related neuritic
pathology [10,45]. However, among 71 cases of PD from the London
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compatible with the caudo-rostral spreading suggested by Braak et al
[31] and 43% did not ﬁt the predicted spread of αSyn inclusion
pathology. The most frequently affected regions were SN and NBM
(100 and 98.5%, respectively), followed by LC and DMV (97 and 92.9%,
respectively). In 7% the DMV was not affected, although αSyn
inclusions were found in SN and/or cortical regions [96]. On the
other hand, in a 68-year-old womanwith late-onset, dopa-responsive
parkinsonism of almost 13 years duration, autopsy revealed severe
neuronal loss with many LBs in DMV but only moderate neuron
depletion (60%) in SNc without any LBs and moderate cell loss with
diffuse αSyn cytoplasmic staining in LC, suggesting unusual manifes-
tation of LB disease [68]. In an autopsy series of 260 elderly subjects
including 71 cases of autopsy proven PD, 38 of DLB,116 AD and 26 age-
matched controls (with positive αSyn pathology in 51% of AD and 31%
of controls), 30% of AD cases with multifocal αSyn pathology but
without clinical EPS showed no involvement of the medullary nuclei
[74]. In another autopsy series of 60 autopsy-conﬁrmed cases of PD
(29 PD with dementia/PDD/ and 31 without dementia, mean age at
death 82.5 years), some early PD symptoms were shown to occur
already in rare cases with LB stage 2 (2.3%), e.g., autonomic and
bladder dysfunctions, sleeping disorders, constipation, orthostatic
hypotension, and depression, and more often in stage 3 (15.0%), in
which most patients clinically revealed stiffness, asymmetric rigidity,
and mild hypomimia but no tremor. Stage 4 (50.0%) and stage 5
(31.7%) showed typical PD-related motor features [3,75]. Thirty-nine
brains (65%) showed almost equal αSyn load in SN, NBM, LC and both
DMV and gigantocellular reticular formation, while 11 brains (18.3%)
revealed considerable αSyn lesions in SN, LC and NBM, but only mild
involvement of DMV. In this material, the most frequently involved
CNS regions were SN (96.7%), NBM (98%), and LC (96.7%), whereas the
DMV was involved in 91.7%. Five brains (8.3%), despite deﬁnite
involvement of SN, LC and NBM in four and additional cingulate gyrus
and limbic cortex involvement in one each, showed no αSyn lesions
and almost no neuronal loss in DMV. The latter cases clinically
presented with rigid-akinetic and L-dopa-responsive PD, with rest
tremor in three and dementia in two cases (one each with frontal and
limbic cortical involvement). Less frequently affected brain regions
were the olfactory bulb (70%), CA 2/3 sector of hippocampus (39%),
previously regarded as a means to differentiate diffuse DLB from PD
[98], and cingulate gyrus and/or frontal cortex (31.6%) [75]. In general,
DMV and SN were found to be equally susceptible nuclei, but
structures even earlier affected by αSyn pathology include the spinal
cord, DMV, olfactory bulb and amygdala [11,31,46,99–101]. The fact
that between 6.3 and even 47% of all clinical and autopsy-conﬁrmed
PD cases obviously do not strictly follow the proposed staging system
of αSyn inclusion pathology and that in 7 to 8.3% the DMV was not
involved despite deﬁnite αSyn pathology in higher brainstem or even
cortical regions [75,76,96] suggests that the proposed ascending
pathway may not be the only possible route of disease progression
and simultaneous involvement of subcortical and cortical regions
appears to be possible. In very few cases of DLB with severe AD
pathology, the amygdala develops αSyn pathology and neuronal loss
prior to the brainstem nuclei, while depletion of cardiac nerves is not
necessarily seen [102]. αSyn pathology beginning in the amygdala
associated with AD [99,101,103] may show rostro-caudal spread to the
entorhinal cortex and midbrain/brainstem regions. However, the
reasons for such deviations from the frequently but not consistently
observed caudo-rostral propagation and for sparing of medullar nuclei
even in clinically manifested PD await further elucidation.
A recent study on the progression of pathology in longitudinally
followed PD patients veriﬁed three different clinico-pathologic
groups: (1.) In a group of younger onset patients presenting with
long clinical duration and LB distributions consistent with the Braak
staging, brainstem LBs dominated in those surviving up to 5 years; by
13 years 50% of cases had a limbic distribution of LBs, and by 18 years,all had at least this pathologic subtype. (2.) About 25% of cases had an
early malignant, dementia-dominant syndrome and severe neocor-
tical disease consistent with DLB. (3.) The last group with older onset,
shorter survival and more complex disease course showed higher LB
loads, suggesting that widespread LB pathology either occurs at the
onset of clinical disease or rapidly inﬁltrates the brain with frequent
concomitant lesions, in particular more plaque pathology, supporting
a more aggressive and linked phenotype. These data suggest that the
different phenotypes cannot be differentiated by pathology alone and
are also not consistent with a unitary concept of the pathogenesis of
LB disease [104].
5. α-Syn pathology in the nervous system and
clinical manifestations
The degree of A9 SN cell loss and the resulting dopamine decrease
in the striatum [105] as well as the reduction of TH and dopamine
transporter (DAT) immunoreactivity in the putamen followed by
caudate nucleus and nucleus accumbens show close correlation to the
duration and severity of motor dysfunction in PD [106]. Akinesia and
rigidity are linked with SN neuronal loss, but are not correlated with
the density of αSyn accumulation in SN [107], and no relationship
between the LB stage and both clinical severity of PD (Hoehn & Yahr
score) and age at death was found [108]. Furthermore, the percentage
of LB bearing neurons in SN is not correlated with disease duration,
and apparently stable over time, involving 39% of SN neurons in
average. This suggests that, during the course of disease, the
destruction of LBs is equal to their production and that they are
destroyed together with the afﬂicted neurons. A mean survival time of
LB bearing neurons was estimated at around 6.2 months, and a
neuronal loss of 71% would be reached after 20 years, matching the
standard progression of the disease [109].
It is unclear, however, whether the accumulation of pathologic AS
in SN correlates with the dopaminergic deﬁcit in the striatum as the
major cause of motor symptoms in PD. DAT immunoreactivity in the
striatum is inversely correlated with the total AS burden in SN but not
with LB counts alone. Nigral TH immunoreactivity did not correlate
with AS immunoreactivity, since it can be preserved in neurons
aggregating AS [110]. These data support the concept of synaptic
dysfunction and/or axonal transport impairment caused by AS
aggregation. A close topographic relationship between TH-negative
neurons, LBs, and neuronal loss has been shown for the SN [111].
Reduced intensity of DAT mRNA in the remaining SN neurons is
associated with reduced AS mRNA and DAT expression in SN, striatum
and amygdala, but not in SN in early stages of PD [112], whereas AS
inclusions and neuritic changes in the neostriatum increase with
disease progression [52]. Detection and staging of LBs alone, therefore,
may not have clinical impact, whereas cytoplasmic and neuritic
accumulation of pathologic AS and, in particular, neuronal loss in the
involved brain areas may have more important implications for
classiﬁcation and staging the progression of the disease process.
Lewy body pathology in the central and peripheral autonomic
system in a neurologically unremarkable elderly human population is
not an infrequent ﬁnding [3,11,55,61,74,76,97,113–115], which was
detected only in comprehensive studies of the whole nervous system.
Comparisons between such studies should account on case selection
and themethods used for detecting LBs [76,97,116–119]. Earlier studies
showed LBs in the brains of 50 elderly persons without extrapyr-
amidal symptoms [61], αSyn pathology in SNc in about 10% of
neurologically unimpaired elderly persons [114] and in midbrain and
limbic cortex in 31% of asymptomatic aged controls with amean age of
82.0 years. These were referred to as iLBD. while multifocal αSyn
pathology in10% of them corresponded to Braak LB stages 4 [74].
Among 241 autopsy cases without clinical evidence of neurologic
disease (average age 78.7 years) from the Mayo Clinic Tissue Registry
(Rochester, MN, USA) 36 cases (15%) with incidental LBs were found
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patients distinguished LB stage 0 (87.3%), stage 1 (incidental LBs,12%),
stage 2 (LBs without attributable clinical symptoms, 3.8%), stage 3 (PD
without dementia, 8.1%), stage 4 (DLB transitional form, 2.1%), and
stage 5 (neocortical DLB, 1.9%) [121], while in a single neurologically
unimpaired subject, widespread and abundant αSyn pathology was
detected [115], whichwas suggested to predict neither extrapyramidal
symptoms (EPS) nor dementia. Among 98 elderly autopsy cases
without PD-associated symptoms, αSyn pathology was found in the
brain, spinal cord and peripheral autonomic system in 17.3% [11].
Among 208 autopsy cases from theMRC CFAS brain donor cohort aged
65+ years (almost 75% over 80 years old, 50% of them demented), 76
brains (36.5%) showed LBs. Only 51% of these conformed to the Braak
LB staging, while 17% had αSyn pathology in a higher region which
was absent in a lower region. A further 29% showed amygdala-
predominant αSyn pathology. Six brains presented predominant
neocortical αSyn pathology with minor involvement of amygdala and
SN [55]. This population-based study showed that 80% of those with
αSyn pathology conformed either to a DLB consensus/Braak stage
pattern (51%) or to amygdala-predominant disease (29%). Amygdala-
predominant αSyn pathology was therefore present in 60% of a DLB/
Braak stage-conforming pattern. The remaining 20% did not ﬁt into
either system of αSyn progression — a previously unreported
population group. A group in which αSyn pathology was predomi-
nantly neocortical, with minimal amygdala involvement and absent
transentorhinal/cingulate lesions (8%), corresponds to the diffuse
cortical form of DLB [56,122]. The MRC CFAS study conﬁrms that αSyn
frequently coexists with AD-type pathology, but suggests that there is
no consistent hierarchy in the progression of the two disease
processes [77]. In the hitherto largest autopsy series of 1720
individuals aged at death N40 years from Kuopio, Finland, the total
frequency of αSyn lesions was 14% [76]. 83% of them showed a
distribution pattern of αSyn lesion comparable to the two current
staging systems of PD and DLB, but 55% of subjects with widespread
αSyn pathology (Braak PD stages 5–6) lacked clinical signs of
dementia (MMSEN26) or EPS. Similarly, among those subjects that
fulﬁlled the McKeith criteria for DLB and displayed only mild
concomitant AD-related pathology, only 48% were demented and
54% displayed EPS. When only demented subjects were included in
the analysis, the correlation between αSyn pathology and dementia
was 85%.17% of all cases showed deviations from the suggested caudo-
rostral disease progression. One subject with EPS was found already in
Braak PD stage 2, whereas none of the cases in stage 4 displayed EPS,
and more importantly, no EPS had been reported in 55% of subjects
who exhibited widespread αSyn pathology (Braak PD stages 5–6), as
compared to the 14% previously reported [31]. These and other results
suggest that the risk for EPS increases with disease progression
though not to the same extent as previously believed. On the other
hand, in large autopsy samples between 30 to 55% of elderly subjects
with widespread αSyn pathology were neuropsychiatrically intact
lacking clinical symptoms or were not classiﬁable [60,74,76].
Initial decline in cognition was postulated to occur already during
stages 3 and 4, i.e. around the same time when initial manifestations
of somatosensory and motor dysfunction appear. Among 88 subjects,
dementia was observed in stage 3 (36%), stage 4 (67%), stage 5 (94%)
and in 100% in stage 6, indicating that increasing cognitive decline
(decreasing MMSE scores) correlated with increasing αSyn stages
[40], which was not conﬁrmed by others [76,123–125]. In the hitherto
largest autopsy study of αSyn pathology in humans, the percentage of
demented persons increased from 0 to 50% between LB stages 3 and 6.
However, when subjects with either EPS or dementia were included,
91 and 94%, respectively, were assigned to PD stages 5–6. This
indicated that only when subjects with clinical symptoms were
included in the analysis, the correlation between stage/severity of
αSyn pathology and EPS and/or dementia was excellent in line with
previous reports [76]. In an autopsy series of 330 elderly patients withclinical parkinsonism (37.6% of which with dementia), only 1.6% of the
demented patients (MMSEb20) showed LB Braak stages 3–5, which
were found in the majority of non-demented PD cases, while 35.5% of
Parkinson–dementia (PDD) cases revealed LB stages 4 or 5 with
superimposed severe Alzheimer pathology (neuritic Braak stages V
and VI). More than half of them showed a strong relationship between
αSyn and tau pathologies, particularly in the limbic system. DLB with
low or high-grade Alzheimer lesions were seen in 40% of PDD patients,
but almost one-third of diffuse DLB cases, i.e. those with mild AD
lesions restricted to amyloid plaques or tau pathology in the limbic
system, did not show considerable cognitive impairment [126].
The clinical relevance of cortical αSyn pathology in relation to
cognitive impairment is amatter of intense debate. Some authors have
emphasized their key causative role [26–28,30], whereas others have
reported abundant LB cortical lesions in non-demented PD patients
[123] as well as in neuropsychiatrically unimpaired elderly subjects
[76,115]. These data clearly indicate that detailed regional assessment
of αSyn pathology, the inter- and intra-rater reliability of which has
recently been reviewed [41], cannot reliably predict the clinical status
observed intra vitam [97]. The neuropathology of PD with andwithout
dementia and DLB shows both similarities and slight differences.
Morphology and immunohistochemistry of cortical and subcortical
LBs and the ascending spreading pattern of αSyn pathology do not
signiﬁcantly differ between both subtypes, the late cortical stages 5
and 6 of LB pathology suggesting overlap or transition between PD
and DLB [2,3,74,127], although DLB often has higher density of cortical
LBs and AD lesions than PDD [128]. The SN and other subcortical
nuclei in DLB show variable neuronal loss often indistinguishable from
sporadic PD, except for an occasionally more severe loss in the ventro
(dorso)lateral tier compared to predominant cell loss in the
medioventral parts of SNc in PD and more frequent involvement by
αSyn deposits of the limbic system, in particular the CA 2/3 subarea of
the cornu Ammonis in DLB than in PD/PDD (79 vs 36%) [2]. A major
morphologic difference is the signiﬁcantly more frequent and severe
load with diffuse amyloid plaques in the striatum in DLB, irrespective
of the severity of cortical AD-type lesions, while non-demented PD
cases are virtually free of Aβ pathology as is the globus pallidus [129–
131]. There are neither correlations between LB density in any brain
area and neuritic Braak AD stages or frequency of neuritic plaques
[132], nor between LBs in cortex and SN, suggesting that DLB should
not be considered a severe form of PD. Whereas LB densities, in
general, cannot separate DLB from PD/PDD, the severity and duration
of dementia appears to be related to both increased hippocampal LB
densities and neuritic plaque grade. A screening algorithm suggesting
that LB density thresholds in parahippocampus may distinguish
demented from non-demented PD cases independent from other
pathologies [133] awaits further conﬁrmation. However, individuals
can show signiﬁcant cognitive disturbancewith no orminimal cortical
LBs and, conversely, widespread cortical LB pathology without
essential cognitive decline [40,123,134]. In the large Finish autopsy
cohort 56% of those subjects where limbic/diffuse neocortical αSyn
pathology combined with mild to moderate AD-related changes
remained cognitively intact. However, when only demented subjects
with severe AD-related pathology (neuritic Braak stages V and VI),
were examined, 85% were assigned to a high likelihood category of
DLB and all of them were demented [76]. Hence, in cognitively
impaired subjects there is a good correlation between dementia and
particular pathologies.
6. Conclusions
Some recent clinico-pathologic studies conﬁrm that the current
staging/categorization systems for can readily be applied to most of
the subjects when assessing regional distribution and progression
patterns of αSyn pathology, although in a certain percentage of cases
this caudo-rostral propagation pattern suggested for PD cannot be
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modiﬁed by other coexisting pathologies or genetic factors [101,135–
137]. Various clinical, biochemical and morphological overlaps
between PD, DLB and AD including co-localization of tau and αSyn
epitopes in LBs suggest that the process of LB formation is triggered, at
least in part, by AD pathology [2,138,139]. Deposition of tau can be
demonstrated in a proportion of LBs, being greatest in neurons
vulnerable to both LB and NFT formation, such as in LC, NBM and
amygdala [140,141]. This suggests that αSyn and tau may be related to
several pathologic processes (bystander effect), which explains the
frequent overlap between synucleinopathies and tauopathies
[142,143]. The collision of two or more processes may occur in the
same brain region or even in single cells in the human brain, e.g., in
LRRK2 mutations [144] and in animal models of PD [145], with
association of phospo-tau and αSyn in both NFTs and LBs [146] and in
vitro promotion of tau aggregation by αSyn and vice versa [147].
Others have suggested that amyloid rather than tau enhances αSyn
pathology in human brain and transgenic mice [137,148]. These
interactions highlight the interface between these and other mis-
folded proteins [143,149] and may represent molecular mechanisms
in overlapping pathology of PD/DLB and AD [150,151], together with
recent biochemical data on tau and β-amyloid [152] challenge the
view of PD and DLB as distinct entities.
The recent MRC CFAS study found no evidence for preponderance
of amygdala-predominant αSyn pathology over the prototypical DLB/
Braak hierarchy in terms of an association with AD [55]. According to
these authors, this does not support the proposed hypothetical link
between αSyn in the amygdala and AD pathology [99,101], and was
explained by the fact that the studies from which these hypotheses
emerged included only clinically referred, i.e. selected cases.
On the other hand, in retrospective studies of unselected autopsy
cohorts up to 50% of cases displaying abundant αSyn pathology had
been reported to be clinically intact without neuropsychiatric deﬁcits.
It has been suggested that the key lesions may develop a considerable
time prior to the appearance of clinical symptoms [84], but the
duration and progression of this “preclinical” phase is still under
discussion. According to functional neuroimaging studies this pre-
clinical periods range from 4.6 to 6.6 years, with an annual decline of
striatal dopamine uptake of 8–10% and of DAT between 5.7 and
6.4 years or 10 to 13%, while others suggested that the preclinical
phase of illness may last somewhat between 5 and 20 years [153].
Higher nigrostriatal dopamine loss has been suggested in early than
late-onset PD [154]. Reduction of striatal dopamine by 57–80% [155]
and DAT loss of 56% or approximately 50% of nigral dopaminergic
neurons cause motor symptoms [156]. Thus, about 50% of dopami-
nergic striatal innervation appears to be sufﬁcient for normal motor
function [105]. Striate dopamine release was 60% reduced in PD
patients, whereas in the frontal cortex it was within normal range,
indicating that it remained preserved even in severe stages of the
disease [157]. Decreased DAT ultimately results in increased dopamine
turnover preposing towards the occurrence of motor complications as
PD progresses [158]. However, recent studies in both movement
disorders and dementing processes demonstrated that some subjects
may tolerate substantial amounts of both αSyn and tau pathology
without deﬁnite clinical manifestation, suggesting considerable
compensatory mechanisms of the aging brain [159–164]. Recent
FDG-PET studies in PD showed only a short metabolic preclinical
period [78]. It should be considered, however, that the biological
signiﬁcance and clinical impact of abnormal αSyn aggregations are
not yet clear. Like other ﬁbrillary proteinaceous inclusions, such as
NFTs or Pick bodies, they may represent end products of reactions to
hitherto unknown neuronal degenerative processes [165]. The
question whether LBs and other αSyn aggregates are cytotoxic and
lead to neuronal death due to production of oxidative stress,
mitochondrial energy deﬁcit and other noxious factors or are
cytoprotective still remains unresolved [166–170]. Biophysical studieshave suggested that rather the protoﬁbrillary than the ﬁbrillary form
of αSyn is cytotoxic [171–173], whereas the LBs and LNs composed of
ﬁbrillary αSyn which are typically observed at autopsy, may be the
structural manifestation of a cytoprotective response designed to
conﬁne and to eliminate cytotoxic proteins or abnormal cytoskeletal
elements [165,174–176]. There is no correlation between the density of
LB formation and neuronal cell loss [177], and the comparatively low
number of neurons containing LBs in any brain region would not be
expected to result from altered synaptic function. Nevertheless,
signiﬁcant intracellular protein aggregation, such as LB formation,
are pathologic processes, reﬂecting changes in the cellular environ-
ment that may ﬁnally contribute to dysfunction of the involved cells.
Recent studies showed development of LBs in grafted neurons in
subjects with PD, suggesting host-to-graft propagation [178].
Existing deﬁnitions and classiﬁcation systems should be based on
an understanding of the underlying pathologic process which, in the
case of synucleinopathies is still incomplete. Therefore, in view of the
caveats discussed above and the inter- and intraindividual biological
variabilities, the neuropathologic staging procedures are instruments
being far from perfect [43,179,180]. Although recent studies indicate
that LB pathology is indeed progressive, the assessment of regional
distribution patterns of αSyn pathology may either evaluate a stage of
degeneration or conversely monitors the level of functional neuro-
protection, concluding that the topographic mapping of αSyn
deposition may be of questionable value, because its is unclear
whether LB pathology is the primary (or solely relevant) pathology in
PD and related disorders [76]. If it is the synucleinopathy that
characterizes and drives idiopathic PD (and DLB) [181], the question
arises about the degree of lesional density that has to be reached to
induce clinical symptoms. The presence of αSyn aggregations, which
have been observed in PD to develop ﬁrst in axons as LNs [16,182], may
ﬁnally damage the parent nerve cell by interfering with axonal
transport [10,140,183–186].
Keeping all these pros and cons in mind, one has to conclude that,
if robust correlations between clinical course and morphologic
changes will be conﬁrmed by future prospective clinico-pathologic
studies, the neuropathologic staging/classiﬁcation systems will need
to be revised accordingly.
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